Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRTX NASDAQ:IZTC NYSE:PLX NASDAQ:PSTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRTXCortexyme$1.89+3.3%$1.31$1.78▼$40.66$56.99M1.4620,672 shs160,022 shsIZTCInvizyne Technologies$9.25$12.23$8.50▼$23.00$103.16MN/A37,647 shs1,872 shsPLXProtalix BioTherapeutics$1.45-3.3%$1.53$0.82▼$3.10$115.43M-0.23601,033 shs514,630 shsPSTIPluristem Therapeutics$1.24$0.95▼$3.45$32.35M1.91715,259 shs2,128 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRTXCortexyme+5.78%+2.81%+34.56%+84.76%+140.09%IZTCInvizyne Technologies0.00%-1.01%-22.73%-8.68%+989,859,900.00%PLXProtalix BioTherapeutics-3.33%+2.84%+3.57%-44.44%+28.32%PSTIPluristem Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRTXCortexymeN/AN/AN/AN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/APLXProtalix BioTherapeutics2.2992 of 5 stars3.53.00.00.00.00.01.9PSTIPluristem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRTXCortexyme 0.00N/AN/AN/AIZTCInvizyne Technologies 0.00N/AN/AN/APLXProtalix BioTherapeutics 3.00Buy$15.00934.48% UpsidePSTIPluristem Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRTXCortexymeN/AN/AN/AN/A$3.97 per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/APLXProtalix BioTherapeutics$59.76M1.93$0.08 per share17.80$0.47 per share3.09PSTIPluristem Therapeutics$20K0.00N/AN/A$1.80 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRTXCortexyme-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/AIZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/APLXProtalix BioTherapeutics$8.31M$0.04N/A4.68N/A-21.03%-30.89%-11.74%N/APSTIPluristem Therapeutics-$49.87M-$1.47N/AN/AN/AN/A-100.63%-55.46%N/ALatest PSTI, PLX, IZTC, and CRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRTXCortexymeN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/APSTIPluristem TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRTXCortexymeN/A9.929.92IZTCInvizyne TechnologiesN/AN/AN/APLXProtalix BioTherapeuticsN/A1.981.27PSTIPluristem Therapeutics0.578.228.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRTXCortexyme63.18%IZTCInvizyne TechnologiesN/APLXProtalix BioTherapeutics16.53%PSTIPluristem Therapeutics16.94%Insider OwnershipCompanyInsider OwnershipCRTXCortexyme27.90%IZTCInvizyne TechnologiesN/APLXProtalix BioTherapeutics6.50%PSTIPluristem Therapeutics5.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRTXCortexyme5530.15 million21.74 millionNot OptionableIZTCInvizyne Technologies296.25 millionN/AN/APLXProtalix BioTherapeutics20079.61 million69.00 millionOptionablePSTIPluristem Therapeutics15332.35 million30.60 millionOptionablePSTI, PLX, IZTC, and CRTX HeadlinesRecent News About These CompaniesEditorial Board — Medscape OncologySeptember 2, 2024 | medscape.comMNBRVF Nabriva Therapeutics plcAugust 18, 2023 | seekingalpha.comPluri CEO Issues Shareholder UpdateJuly 25, 2022 | finance.yahoo.comPluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional IndustriesJuly 25, 2022 | benzinga.comPluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional IndustriesJuly 25, 2022 | finance.yahoo.comPluristem (PSTI) Phase III Study Misses Goal, Stock DownJuly 14, 2022 | finance.yahoo.comPluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture SurgeryJuly 13, 2022 | finance.yahoo.comPluristem's Phase 3 Study Of PLX-PAD To Treat Muscle Injury Does Not Meet Primary GoalJuly 13, 2022 | markets.businessinsider.comPluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture SurgeryJuly 13, 2022 | finance.yahoo.comPluristem: Fiscal Q3 Earnings SnapshotMay 10, 2022 | apnews.comAPluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New PartnershipMarch 28, 2022 | finance.yahoo.comPluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trialMarch 23, 2022 | seekingalpha.comPluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood TransfusionsMarch 23, 2022 | finance.yahoo.comPluristem Therapeutics, Inc. Common Stock (PSTI)March 21, 2022 | nasdaq.comPluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint VentureMarch 8, 2022 | finance.yahoo.comPluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food PlatformFebruary 24, 2022 | finance.yahoo.comPluristem: Fiscal Q2 Earnings SnapshotFebruary 8, 2022 | timesunion.comTWhat Are The Analysts’ Predictions For Pluristem Therapeutics Inc. (NASDAQ: PSTI)?January 18, 2022 | stocksregister.comSThinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?January 12, 2022 | marketwatch.comPluristem Therapeutics Inc. (NASDAQ: PSTI) Is On The RiseJanuary 11, 2022 | stocksregister.comSNew MarketBeat Followers Over TimeMedia Sentiment Over TimePSTI, PLX, IZTC, and CRTX Company DescriptionsCortexyme NASDAQ:CRTX$1.89 +0.06 (+3.28%) As of 07/18/2025Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Invizyne Technologies NASDAQ:IZTC$9.25 0.00 (0.00%) As of 07/18/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.Protalix BioTherapeutics NYSE:PLX$1.45 -0.05 (-3.33%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 07/18/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Pluristem Therapeutics NASDAQ:PSTIPluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
